Antiangiogenic therapies based on tyrosine kinase inhibitors (2, 3) and monoclonal antibodies against vascular endothelial growth factor (VEGF) or its receptor (4) have proven beneficial for the treatment of cancer and retinal vasoproliferative diseases (5). Here, VEGFA is linked to cancer.